EDINBURGH, Scotland, Jan. 18,
2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC
BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage
biotechnology company developing platform allogeneic gamma-delta T
cell therapies for cancer and other indications, today announced
its participation at the upcoming Sequire Investor Summit 2024
scheduled for January 23-25, 2024 at
the Condado Vanderbilt Hotel in San Juan,
Puerto Rico.
TC BioPharm CEO, Bryan Kobel,
will conduct in person one-on-one meetings throughout the
conference and deliver the Company's presentation to registered
participants as shown below.
TC BioPharm Sequire Investor Summit 2024 Presentation
Date: Wednesday, January 24 at
1:30 PM ET - Track 3 Salon Azul
Location: Condado Vanderbilt Hotel in San
Juan, Puerto Rico
For more information about the Sequire Investor Summit,
including registration details or to schedule a 1x1 meeting, please
visit the official event website
at https://puertorico.srax.com/ or
contact ir@tcbiopharm.com
About TC BioPharm (Holdings) PLC
TC BioPharm is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of gamma-delta T cell therapies
for the treatment of cancer with human efficacy data in acute
myeloid leukemia. Gamma-delta T cells are naturally occurring
immune cells that embody properties of both the innate and adaptive
immune systems and can intrinsically differentiate between healthy
and diseased tissue. TC BioPharm uses an allogeneic approach in
both unmodified and CAR modified gamma-delta T cells to effectively
identify, target and eradicate both liquid and solid tumors in
cancer.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of
acute myeloid leukemia using the Company's proprietary allogeneic
CryoTC technology to provide frozen product to clinics worldwide.
TC BioPharm also maintains a robust pipeline for future indications
in solid tumors as well as a significant IP/patent portfolio in the
use of CARs with gamma-delta T cells and owns our manufacturing
facility to maintain cost and product quality controls.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-to-present-at-the-sequire-investor-summit-302038056.html
SOURCE TC BioPharm